KIT and systemic mastocytosis: Importantly, TRKA activation also affected the response of both HMC-1.2 cells harboring KIT D816V mutation and primary mast cells isolated from patients with SM associated with KIT D816V to KIT-targeted therapy (Figures 2F, 2G, 3A–3E, Supplementary Figure 4).